However, in the ccRCC cohort, the high NEK2 expression group did not differ from the low NEK2 expression group in terms of enhancing tumor activity and antitumor activity (Fig. 3C). This evidence concerns the gene NEK2 and nonpapillary renal cell carcinoma.